Grasp management to improve efficiency and increase production
Release time:
2020-07-22
Grasp Management Increase Efficiency Increase Output
Pharmaceutical Company 2018 Outstanding Management Worker Jinxi Pharmaceutical Factory Yang Xinfeng
I started from 2008 , starting from the raw material workshop operator, he has served as QA , technologist, assistant director, deputy director of preparation workshop and director of raw material workshop. Looking back on the 10 years that I have gone through, from the production of bulk drugs to the production of preparation products, from the management of preparation workshop to the management of raw material workshop, I have come from one post to another, so that I can find my own shortcomings and improve my work ability gradually.
This time I went back to the raw material workshop to engage in workshop management. Facing the brand-new raw material workshop, I started to learn again from the production equipment, safety and environmental protection equipment and pipeline direction. Starting from the production process and post operation, I started to follow the class. Through their own learning, and gradually find out the status of the equipment, staff skills and the workshop site management space. Therefore, I organized the workshop management personnel to readjust the division of labor, dividing the workshop management work into production quality, safety and environmental protection, equipment operation and maintenance, laboratory tests and other parts, setting up responsible persons, defining their respective work processes, and improving the work efficiency of the workshop management team. The raw material workshop management personnel also reached a consensus to keep the telephone 24 open to meet the requirements of workshop production safety. At the same time, through workshop evaluation, select the team leader among the excellent operators, explore the working mode of the team in the raw material workshop, control the source of safety and environmental protection work such as equipment safety, safety inspection and rectification, and potential safety hazard investigation in the workshop, and reduce the safety and environmental protection risks in the workshop. At the same time, I took the initiative to ask young college students with professional skills to provide them with learning opportunities and exercise platforms to promote the development of new team forces.
Workshop management cannot be separated from human management. What is related to the vital interests of employees is the workshop scheduling system. A fair and just system must be formed, which not only restricts the compliance of management work, but also restricts the standardization of employee operation. To set a benchmark and set a typical example, guide employees to use their brains and offer suggestions. Through positive incentives, employees are rewarded for their suggestions for improvement. At the same time, the violation of labor discipline, process discipline, equipment safety and other acts of assessment and punishment.
Through the development of various workshop management work and the joint efforts of all workshop personnel, the average output of cefmenoxime hydrochloride per batch in the raw material workshop in 2018 increased by 2.5kg , the average output of amlodipine aspartate per batch increased by 1.1kg , and the stability of paroxetine hydrochloride process was strengthened. There are no safety and environmental accidents in the workshop throughout the year. Technical research Aspartate amlodipine free base and methyl oxime raw material particle size control project completed, to achieve the desired results. The annual material consumption was reduced by more than $41.2 million. Workshop attrition 4 people. Complete the equipment transformation and process verification of new product aminocaproic acid, complete the production of new products in North Carolina, and a number of energy-saving and consumption-reducing transformation work. (According to Yang Xinfeng's speech at the summary and commendation meeting of the pharmaceutical company)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page